Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes.
作者信息
Gill Dipender, Burgess Stephen
机构信息
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, United Kingdom (D.G.).
Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health (S.B.).
出版信息
Circ Genom Precis Med. 2020 Oct;13(5):551-553. doi: 10.1161/CIRCGEN.120.003061. Epub 2020 Aug 13.
Abstract
摘要
相似文献
1
Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes.利用与循环中活化因子X（FXa）水平相关的基因变异来替代FXa抑制对心血管结局的影响。
Circ Genom Precis Med. 2020 Oct;13(5):551-553. doi: 10.1161/CIRCGEN.120.003061. Epub 2020 Aug 13.
2
Innovative Three-Step Microwave-Promoted Synthesis of -Propargyltetrahydroquinoline and 1,2,3-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design, Synthesis, and Biological Evaluation.创新的三步微波促进 - 炔丙基四氢喹啉和 1,2,3-三唑衍生物的合成作为潜在的因子 Xa（FXa）抑制剂：药物设计、合成和生物学评价。
Molecules. 2020 Jan 23;25(3):491. doi: 10.3390/molecules25030491.
3
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.在 ENGAGE AF-TIMI 48 试验中，将内源性因子 Xa 活性（一种具有生物学相关性的药效动力学标志物）与依度沙班的血浆浓度和临床结局联系起来。
Circulation. 2018 Oct 30;138(18):1963-1973. doi: 10.1161/CIRCULATIONAHA.118.033933.
4
Identification of AcAP5 as a novel factor Xa inhibitor with both direct and allosteric inhibition.鉴定AcAP5为一种具有直接和变构抑制作用的新型凝血因子Xa抑制剂。
Biochem Biophys Res Commun. 2017 Jan 29;483(1):495-501. doi: 10.1016/j.bbrc.2016.12.116. Epub 2016 Dec 19.
5
Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation.邻氨基苯甲酰胺衍生物作为潜在的凝血因子Xa抑制剂的鉴定：药物设计、合成及生物学评价。
Eur J Med Chem. 2015 May 5;95:388-99. doi: 10.1016/j.ejmech.2015.03.052. Epub 2015 Mar 25.
6
Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.新型基于邻氨基苯甲酰胺的凝血因子Xa抑制剂：药物设计、合成及生物学评价
Molecules. 2016 Apr 14;21(4):491. doi: 10.3390/molecules21040491.
7
Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations.发色底物法抗 FXa 检测在利伐沙班和阿哌沙班治疗患者中经低分子肝素校准：可能性和局限性。
Biochem Med (Zagreb). 2020 Feb 15;30(1):010702. doi: 10.11613/BM.2020.010702. Epub 2019 Dec 15.
8
Synthesis and biological evaluation of Isosteviol derivatives as FXa inhibitors.Isosteviol 衍生物作为 FXa 抑制剂的合成与生物评价。
Bioorg Med Chem Lett. 2020 Jan 15;30(2):126585. doi: 10.1016/j.bmcl.2019.07.044. Epub 2019 Jul 24.
9
Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors.基于邻氨基苯甲酰胺的衍生物作为凝血因子Xa抑制剂的合成与评价
Oncotarget. 2017 Jun 6;8(23):37186-37199. doi: 10.18632/oncotarget.16427.
10
Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors.作为凝血因子Xa抑制剂的3,4-二氨基苯甲酰衍生物的合成。
Eur J Med Chem. 2015 Aug 28;101:41-51. doi: 10.1016/j.ejmech.2015.06.012. Epub 2015 Jun 17.
引用本文的文献
1
Optimizing treatment of cardiovascular risk factors in cerebral small vessel disease using genetics.利用遗传学优化脑小血管病心血管危险因素的治疗
Brain. 2024 Dec 11. doi: 10.1093/brain/awae399.
2
Mendelian randomization as a tool to inform drug development using human genetics.孟德尔随机化作为一种利用人类遗传学为药物研发提供信息的工具。
Camb Prism Precis Med. 2023 Feb 8;1:e16. doi: 10.1017/pcm.2023.5. eCollection 2023.
3
Genetically Determined Circulating Lactase/Phlorizin Hydrolase Concentrations and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study.遗传决定的循环乳糖酶/根皮苷水解酶浓度与结直肠癌风险的关系：一项两样本孟德尔随机化研究。
Nutrients. 2024 Mar 12;16(6):808. doi: 10.3390/nu16060808.
4
Using genetic association data to guide drug discovery and development: Review of methods and applications.利用遗传关联数据指导药物发现和开发：方法和应用综述。
Am J Hum Genet. 2023 Feb 2;110(2):195-214. doi: 10.1016/j.ajhg.2022.12.017.
5
Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches.结合孟德尔随机化和共定位证据：方法的回顾与比较。
Am J Hum Genet. 2022 May 5;109(5):767-782. doi: 10.1016/j.ajhg.2022.04.001. Epub 2022 Apr 21.
6
Genetic Evidence Supporting Fibroblast Growth Factor 21 Signalling as a Pharmacological Target for Cardiometabolic Outcomes and Alzheimer's Disease.支持成纤维细胞生长因子 21 信号传导作为心脏代谢结局和阿尔茨海默病的药理学靶点的遗传证据。
Nutrients. 2021 Apr 29;13(5):1504. doi: 10.3390/nu13051504.
7
Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study.基于遗传关联的凝血因子抑制与心血管疾病风险：一项孟德尔随机化研究。
J Am Heart Assoc. 2021 Apr 20;10(8):e019644. doi: 10.1161/JAHA.120.019644. Epub 2021 Apr 9.
本文引用的文献
1
Rare variants lowering the levels of coagulation factor X are protective against ischemic heart disease.降低凝血因子X水平的罕见变异对缺血性心脏病具有保护作用。
Haematologica. 2020 Jul;105(7):e365-e369. doi: 10.3324/haematol.2019.237750. Epub 2019 Nov 7.
2
Genetically Determined FXI (Factor XI) Levels and Risk of Stroke.遗传决定的 FXI（因子 XI）水平与卒中风险。
Stroke. 2018 Nov;49(11):2761-2763. doi: 10.1161/STROKEAHA.118.022792.
3
Genomic atlas of the human plasma proteome.人类血浆蛋白质组基因组图谱。
Nature. 2018 Jun;558(7708):73-79. doi: 10.1038/s41586-018-0175-2. Epub 2018 Jun 6.
4
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
5
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.阿哌沙班与依诺肝素预防髋关节置换术后血栓形成的比较。
N Engl J Med. 2010 Dec 23;363(26):2487-98. doi: 10.1056/NEJMoa1006885.
Zotero 插件